USPTO Art Unit 1646 Prosecution Statistics

Art Unit Information

Art Unit: 1646
Group: 1640
Tech Center: 1600
Total Cases: 12,431
Last Active: February 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19063190COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAMEFebruary 2025June 2025Allow310NoNo
18919082COMPOSITIONS FOR TREATING CANCEROctober 2024June 2025Allow811NoNo
18904628ANTIBODY DRUG CONJUGATE (ADC) TARGETING NECTIN 4 AND COMPRISING AN EXATECAN PAYLOADOctober 2024July 2025Allow920YesNo
18897951BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGFSeptember 2024June 2025Allow810NoNo
18896098ANTIBODY-DRUG COMPLEX CONTAINING TOLL-LIKE RECEPTOR 7/8 DUAL AGONIST COMPOUNDSeptember 2024March 2025Allow510NoNo
18802353COMPOUND COMPRISING FC-BINDING UNIT, AND CONJUGATE PREPARED USING SAMEAugust 2024January 2025Allow610NoNo
18792921IgE BINDING PROTEINS AND USES THEREOFAugust 2024December 2024Allow501YesNo
18787110IMMOBILIZED ENDOGLYCOSIDASE FUSION PROTEIN AND USE THEREOFJuly 2024April 2025Allow921NoNo
18777688METHOD FOR IMPROVING CELL ADHESION WITH SMECTITE CLAYJuly 2024October 2024Allow210NoNo
18777712CELL ADHESION METHOD WITH SODIUM MONTMORILLONITEJuly 2024September 2024Allow210NoNo
18777706METHOD OF INCREASING CELL ADHESION WITH PALYGORSKITEJuly 2024September 2024Allow210NoNo
18740390INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAMEJune 2024September 2024Allow301YesNo
18731223LIPID NANOPARTICLE FORMULATIONS AND COMPOSITIONSMay 2024January 2025Allow820YesNo
18668012COVALENT MULTI-SPECIFIC ANTIBODYMay 2024September 2024Allow400YesNo
18660672ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOFMay 2024April 2025Allow1111NoNo
18656081ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORSMay 2024June 2025Allow1310NoNo
18656166ANTIBODIES TARGETING LIV-1 AND USES THEREOFMay 2024August 2024Allow300YesNo
18648976ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOFApril 2024September 2024Allow500YesNo
18640824COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOFApril 2024August 2024Allow410NoNo
18638229BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFApril 2024January 2025Allow911YesNo
18637283ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCERApril 2024September 2024Allow510YesNo
18618414ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAMEMarch 2024May 2025Allow1310NoNo
18618634METHODS OF TREATING COMPLEMENT-MEDIATED DISEASEMarch 2024January 2025Allow1021YesNo
18612767DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIESMarch 2024March 2025Allow1211YesNo
18612579MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPYMarch 2024June 2024Allow300YesNo
18596217ANTI-INFLUENZA NEURAMINIDASE MONOCLONAL ANTIBODIES AND USES THEREOFMarch 2024May 2025Allow1521NoNo
18593711SYSTEMS TARGETING PSMA AND CA9March 2024January 2025Allow1001YesNo
18423752ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTSJanuary 2024April 2024Allow300YesNo
18415608HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3January 2024May 2025Allow1510NoNo
18411436ANTI-CD37 ANTIBODY-DRUG CONJUGATEJanuary 2024July 2024Allow601YesNo
18409450GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERSJanuary 2024November 2024Allow1020YesNo
18405977BINDING MOLECULESJanuary 2024August 2024Allow800YesNo
18402596COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHYJanuary 2024April 2024Allow410YesNo
18394409METHODS OF TREATING A NEOPLASIA WITH IL-15-BASED MOLECULES AND CTLA-4 ANTIBODYDecember 2023June 2024Allow610YesNo
18393436VACCINIA VIRUS RECOMBINANT A33R PROTEIN AND KIT FOR DIAGNOSING ANTIBODIES AGAINST ORTHOPOXVIRUS COMPRISING THE SAMEDecember 2023November 2024Allow1110NoNo
18570249ANTI-PDL1 ANTIBODIES AND USES THEREOFDecember 2023March 2025Abandon1501NoNo
18570578ANTI-CD3 CONSTRUCTS AND USES THEREOFDecember 2023October 2024Allow1010YesNo
18526598IL-15-BASED FUSIONS TO IL-12 AND IL-18December 2023February 2024Allow301YesNo
18514019Cancer Cytotoxic Exosome Formulations and Methods for Use in Treating CancerNovember 2023June 2025Allow1920YesNo
18511591ANTI-B7H3 ANTIBODY-DRUG CONJUGATE AND USE THEREOFNovember 2023June 2024Allow710YesNo
18510412COMBINATION THERAPIES WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES AND THIRD GENERATION EGFR TYROSINE KINASE INHIBITORSNovember 2023June 2025Allow1920NoNo
18503564COMPOSITIONS AND METHODS FOR USING FIXED BIOLOGICAL SAMPLESNovember 2023July 2024Allow911NoNo
18501741DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow401YesNo
18490581PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERSOctober 2023August 2024Allow1010YesNo
18484244METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLSOctober 2023May 2024Allow710YesNo
18466103MAGE-A4 PEPTIDE DUAL T CELL ENGAGERSSeptember 2023July 2024Allow1011YesNo
18453404Anti-BCMA Antibody Drug Conjugate Combination Treatment for CancerAugust 2023October 2024Allow1410NoNo
18448294METHODS FOR TREATING AN OCULAR CONDITION WITH CELLULAR FIBRONECTIN COMPOSITIONSAugust 2023January 2024Allow510NoNo
18446032ANTIBODIES BINDING TO CD3 and CD19August 2023September 2024Allow1401NoNo
18366183METHOD OF TREATING POST-TRAUMATIC STRESS DISORDERAugust 2023May 2025Allow2120YesNo
18363417CHIMERIC ANTIGEN RECEPTORS TARGETING ABNORMAL GLYCOBIOLOGYAugust 2023May 2025Allow2210NoNo
18225567PROTEIN-ANTIVIRAL COMPOUND CONJUGATESJuly 2023February 2025Allow1910YesNo
18272337PROTOCOL TO MINIMIZE CALCINEURIN INHIBITOR NEPHROTOXICITYJuly 2023May 2025Abandon2201NoNo
18351374MATERIALS AND METHODS FOR PERFORMING HISTOCHEMICAL ASSAYS FOR HUMAN PRO-EPIREGULIN AND AMPHIREGULINJuly 2023May 2025Allow2210YesNo
18349983ONCOLYTIC VIRUS VECTOR AND APPLICATION THEREOFJuly 2023March 2024Allow810YesNo
18346437AFFINITY MOLECULES AND METHODS FOR THEIR USEJuly 2023April 2024Allow901NoNo
18342874NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE II AND METHODS OF PRODUCING THE SAMEJune 2023December 2023Allow510NoNo
18214282ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2023October 2023Allow400YesNo
18340421COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIAJune 2023March 2024Allow810NoNo
18339147METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONISTJune 2023December 2023Allow610NoNo
18210250NANOCOMPOSITE INCLUDING ABSCISIC ACID-LOADED COLLAGEN NANOPARTICLESJune 2023June 2024Abandon1221YesNo
18334582CD70 COMBINATION THERAPYJune 2023January 2025Abandon1920NoNo
18334911MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOFJune 2023November 2023Allow501NoNo
18208485GLP-1 RECEPTOR AGONISTS IN DEMENTIAJune 2023March 2024Abandon910NoNo
18332366CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORSJune 2023July 2024Allow1410NoNo
18329987EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITYJune 2023August 2024Allow1411NoNo
18328707COMBINATION PRODUCT FOR THE TREATMENT OF CANCERJune 2023April 2025Abandon2220NoNo
18323438TrkA ANTIBODY AND APPLICATION THEREOFMay 2023April 2024Allow1111NoNo
18323013DUAL CONJUGATION PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATESMay 2023May 2025Allow2300YesNo
18321820IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2023April 2025Allow2310NoNo
18320869ANTI-CD71 ACTIVATABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOFMay 2023March 2025Abandon2210NoNo
18319903INTERLEUKIN-18 RECEPTOR BINDING POLYPEPTIDES AND USES THEREOFMay 2023September 2024Abandon1601NoNo
18314727IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODSMay 2023April 2025Allow2310NoNo
18313134TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEINMay 2023October 2023Allow610NoNo
18308512METHOD FOR PREPARING A PORCINE-DERIVED INTERFERON-DELTA 5 AND APPLICATION OF PORCINE-DERIVED INTERFERON-DELTA 5April 2023January 2024Allow910NoNo
18140214Diabetes BiomarkersApril 2023May 2025Abandon2511NoNo
18304172Engineered Human IL-21 Cytokines and Methods for Using the SameApril 2023April 2024Allow1211YesNo
18303506MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHYApril 2023December 2023Allow801NoNo
18297280USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTAApril 2023August 2024Abandon1610NoNo
18130757ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPINGApril 2023April 2024Allow1311YesNo
18295645RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOFApril 2023April 2025Allow2500YesNo
18295226T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOFApril 2023June 2025Allow2711NoNo
18192715B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023March 2025Allow2410NoNo
18192226COMPOSITIONS AND METHODS FOR TREATING SOLID TUMORSMarch 2023April 2025Abandon2501NoNo
18189443B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023February 2025Allow2310NoNo
18189448B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSMarch 2023February 2025Allow2310NoNo
18123569METHODS OF ALTERING BONE GROWTH BY ADMINISTRATION OF SOST OR WISE ANTAGONIST OR AGONISTMarch 2023July 2023Allow410NoNo
18183676FORMATION OF BONEMarch 2023June 2024Abandon1510NoNo
18182682Fusion Proteins Having a Toxin and Cancer Marker, Nanoparticles, and Uses Related TheretoMarch 2023June 2025Allow2710NoNo
18181666Fusion protein comprising fibroblast growth factor 19 (FGF 19) and glucagon-like peptide-1March 2023October 2023Allow710NoNo
18181802METHOD FOR IDENTIFYING NEOANTIGENS ON CANCER CELLS BY USING XENOANTIBODIESMarch 2023June 2025Abandon2710NoNo
18120020EXPRESSION AND SECRETION SYSTEMMarch 2023May 2025Abandon2610NoNo
18118105THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOFMarch 2023December 2024Allow2120NoNo
18117089ANTIBODY-DRUG CONJUGATEMarch 2023June 2024Allow1600NoNo
18116758COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF SKINMarch 2023February 2024Abandon1101NoNo
18176913USE OF G-CSF ANTIBODY FOR TREATMENT OF PULMONARY FIBROSISMarch 2023May 2023Allow300YesNo
18176957SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODYMarch 2023April 2023Allow200YesNo
18175112METHOD FOR TREATING NEOPLASIA WITH AN ANTI-CD38 ANTIBODY AND AN IL-15:IL-15R COMPLEXFebruary 2023January 2024Allow1020YesNo
18175148AMANITIN CONJUGATESFebruary 2023September 2024Allow1910NoNo
18170154B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODSFebruary 2023August 2024Allow1700NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1646.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
91
Examiner Affirmed
68
(74.7%)
Examiner Reversed
23
(25.3%)
Reversal Percentile
15.7%
Lower than average

What This Means

With a 25.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1256
Allowed After Appeal Filing
207
(16.5%)
Not Allowed After Appeal Filing
1049
(83.5%)
Filing Benefit Percentile
1.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 16.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1646 - Prosecution Statistics Summary

Executive Summary

Art Unit 1646 is part of Group 1640 in Technology Center 1600. This art unit has examined 12,431 patent applications in our dataset, with an overall allowance rate of 51.8%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1646's allowance rate of 51.8% places it in the 8% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1646 receive an average of 1.77 office actions before reaching final disposition (in the 44% percentile). The median prosecution time is 32 months (in the 31% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.